The Valley Desk

NCT04360096 · Interventional trial

Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19

Overall registry status Terminated

Phase 2 · Phase 3

Conditions ALI, ARDS, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), COVID, Dyspnea, SARS-CoV 2

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov